Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsORALGeneric

LEXIVA

FOSAMPRENAVIR CALCIUM

Standard Dose
EQ 50MG BASE/ML
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Discontinued
Summary

Approval overview LEXIVA is listed in Drugs@FDA under application 022116 (NDA).

Review priority: STANDARD Marketing status: Discontinued Active ingredient FOSAMPRENAVIR CALCIUM Form and strength SUSPENSION;ORAL - EQ 50MG BASE/ML Sponsor VIIV HLTHCARE Submission history Latest submission status date: 2019-03-28 00:00:00.

Structured Monograph

Clinical summary

Approval overview LEXIVA is listed in Drugs@FDA under application 022116 (NDA). Review priority: STANDARD Marketing status: Discontinued Active ingredient FOSAMPRENAVIR CALCIUM Form and strength SUSPENSION;ORAL - EQ 50MG BASE/ML Sponsor VIIV HLTHCARE Submission history Latest submission status date: 2019-03-28 00:00:00. Submission type: SUPPL.

Monitoring

  • • Marketing status: Discontinued
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.